RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
Eligible age
2.5–18 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy
Sponsor: The Hospital for Sick Children
Where it's recruiting
San Francisco
Kansas City
New York
Chapel Hill
Columbus
Charleston
Source: ClinicalTrials.gov · NCT03118986 · last updated 2025-10-08